<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7358648\results\search\disease\results.xml">
  <result pre="Microbiology1664-302XFrontiers Media S.A. pmcid: 7358648 doi: 10.3389/fmicb.2020.01434 : Microbiology: Review" exact="Secondary" post="Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as"/>
  <result pre="Media S.A. pmcid: 7358648 doi: 10.3389/fmicb.2020.01434 : Microbiology: Review Secondary" exact="Bacterial Infections" post="During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to"/>
  <result pre="S.A. pmcid: 7358648 doi: 10.3389/fmicb.2020.01434 : Microbiology: Review Secondary Bacterial" exact="Infections" post="During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to"/>
  <result pre="7358648 doi: 10.3389/fmicb.2020.01434 : Microbiology: Review Secondary Bacterial Infections During" exact="Pulmonary" post="Viral Disease: Phage Therapeutics as Alternatives to Antibiotics? ManoharPrasanth12â€"/>
  <result pre="doi: 10.3389/fmicb.2020.01434 : Microbiology: Review Secondary Bacterial Infections During Pulmonary" exact="Viral" post="Disease: Phage Therapeutics as Alternatives to Antibiotics? ManoharPrasanth12â€ LohBelinda1â€"/>
  <result pre="2The Second Affiliated Hospital, School of Medicine, Zhejiang UniversityHangzhouChina[], 3Antibiotic" exact="Resistance" post="and Phage Therapy Laboratory, School of Biosciences and Technology,"/>
  <result pre="of Biosciences and Technology, Vellore Institute of TechnologyVelloreIndia[], 4Department of" exact="Infectious" post="Diseases, Sir Run Run Shaw Hospital, School of Medicine,"/>
  <result pre="equally to this work This article was submitted to Antimicrobials," exact="Resistance" post="and Chemotherapy, a section of the journal Frontiers in"/>
  <result pre="is permitted which does not comply with these terms. Abstract" exact="Secondary" post="bacterial infections manifest during or after a viral infection(s)"/>
  <result pre="permitted which does not comply with these terms. Abstract Secondary" exact="bacterial infections" post="manifest during or after a viral infection(s) and can"/>
  <result pre="which does not comply with these terms. Abstract Secondary bacterial" exact="infections" post="manifest during or after a viral infection(s) and can"/>
  <result pre="terms. Abstract Secondary bacterial infections manifest during or after a" exact="viral" post="infection(s) and can lead to negative outcomes and sometimes"/>
  <result pre="and development of clinical interventions is largely focused on the" exact="primary" post="pathogen, with research on any secondary infection(s) being neglected."/>
  <result pre="largely focused on the primary pathogen, with research on any" exact="secondary" post="infection(s) being neglected. Here we highlight the impact of"/>
  <result pre="secondary infection(s) being neglected. Here we highlight the impact of" exact="secondary" post="bacterial infections and in particular those caused by antibiotic-resistant"/>
  <result pre="infection(s) being neglected. Here we highlight the impact of secondary" exact="bacterial infections" post="and in particular those caused by antibiotic-resistant strains, on"/>
  <result pre="being neglected. Here we highlight the impact of secondary bacterial" exact="infections" post="and in particular those caused by antibiotic-resistant strains, on"/>
  <result pre="infections and in particular those caused by antibiotic-resistant strains, on" exact="disease" post="outcomes. We describe possible non-antibiotic treatment options, when small"/>
  <result pre="options, when small molecule drugs have no effect on the" exact="bacterial" post="pathogen and explore the potential of phage therapy and"/>
  <result pre="phage therapy and phage-derived therapeutic proteins and strategies in treating" exact="secondary" post="bacterial infections, including their application in combination with chemical"/>
  <result pre="therapy and phage-derived therapeutic proteins and strategies in treating secondary" exact="bacterial infections," post="including their application in combination with chemical antibiotics. secondary"/>
  <result pre="bacterial infections, including their application in combination with chemical antibiotics." exact="secondary" post="bacterial infection pulmonary viruses SARS-CoV-2 COVID-19 phage therapy phage"/>
  <result pre="infections, including their application in combination with chemical antibiotics. secondary" exact="bacterial infection" post="pulmonary viruses SARS-CoV-2 COVID-19 phage therapy phage endolysins fig-count:"/>
  <result pre="including their application in combination with chemical antibiotics. secondary bacterial" exact="infection" post="pulmonary viruses SARS-CoV-2 COVID-19 phage therapy phage endolysins fig-count:"/>
  <result pre="their application in combination with chemical antibiotics. secondary bacterial infection" exact="pulmonary" post="viruses SARS-CoV-2 COVID-19 phage therapy phage endolysins fig-count: table-count:"/>
  <result pre="past two decades have seen the emergence of four severe" exact="viral" post="outbreaks including the 2002 Severe Acute Respiratory Syndrome (SARS)"/>
  <result pre="the emergence of four severe viral outbreaks including the 2002" exact="Severe" post="Acute Respiratory Syndrome (SARS) Coronavirus (CoV) epidemic, the 2009"/>
  <result pre="emergence of four severe viral outbreaks including the 2002 Severe" exact="Acute" post="Respiratory Syndrome (SARS) Coronavirus (CoV) epidemic, the 2009 influenza"/>
  <result pre="of four severe viral outbreaks including the 2002 Severe Acute" exact="Respiratory" post="Syndrome (SARS) Coronavirus (CoV) epidemic, the 2009 influenza A"/>
  <result pre="four severe viral outbreaks including the 2002 Severe Acute Respiratory" exact="Syndrome" post="(SARS) Coronavirus (CoV) epidemic, the 2009 influenza A H1N1"/>
  <result pre="epidemic, the 2009 influenza A H1N1 pandemic, 2012 Middle East" exact="Respiratory" post="Syndrome (MERS) outbreak, and most recently the COVID-19 pandemic."/>
  <result pre="the 2009 influenza A H1N1 pandemic, 2012 Middle East Respiratory" exact="Syndrome" post="(MERS) outbreak, and most recently the COVID-19 pandemic. Emergence"/>
  <result pre="434,000 deaths (as of June 15, 2020), a far greater" exact="disease" post="burden than SARS and MERS (Guarner, 2020; Kannan et"/>
  <result pre="The spectrum of clinical presentations of COVID-19 is highly variable;" exact="infections" post="range from being asymptomatic to severe viral pneumonia with"/>
  <result pre="is highly variable; infections range from being asymptomatic to severe" exact="viral pneumonia" post="with respiratory failure, often leading to death (Li et"/>
  <result pre="highly variable; infections range from being asymptomatic to severe viral" exact="pneumonia" post="with respiratory failure, often leading to death (Li et"/>
  <result pre="infections range from being asymptomatic to severe viral pneumonia with" exact="respiratory" post="failure, often leading to death (Li et al., 2020)."/>
  <result pre="replication or attachment of the virus, a major consequence of" exact="disease" post="progression in patients at later stages of infection, are"/>
  <result pre="disease progression in patients at later stages of infection, are" exact="secondary" post="bacterial infections. At least one in seven COVID-19 patients"/>
  <result pre="progression in patients at later stages of infection, are secondary" exact="bacterial infections." post="At least one in seven COVID-19 patients was found"/>
  <result pre="COVID-19 patients was found to be additionally infected with a" exact="secondary" post="bacterial infection with 50% of the fatalities during the"/>
  <result pre="patients was found to be additionally infected with a secondary" exact="bacterial infection" post="with 50% of the fatalities during the SARS-CoV-2 epidemic"/>
  <result pre="was found to be additionally infected with a secondary bacterial" exact="infection" post="with 50% of the fatalities during the SARS-CoV-2 epidemic"/>
  <result pre="fatalities during the SARS-CoV-2 epidemic caused by untreated or untreatable" exact="secondary" post="bacterial infections, in most cases in the lung (Zhou"/>
  <result pre="during the SARS-CoV-2 epidemic caused by untreated or untreatable secondary" exact="bacterial infections," post="in most cases in the lung (Zhou et al.,"/>
  <result pre="treated with antibiotics to attempt to prevent the occurrence of" exact="secondary" post="bacterial infections. Any surge in antibiotic use during the"/>
  <result pre="with antibiotics to attempt to prevent the occurrence of secondary" exact="bacterial infections." post="Any surge in antibiotic use during the COVID-19 pandemic"/>
  <result pre="have a detrimental effect on antibiotic resistance rates for nosocomial" exact="bacterial" post="pathogens, fueling global growth of antibiotic resistant bacterial pathogens"/>
  <result pre="for nosocomial bacterial pathogens, fueling global growth of antibiotic resistant" exact="bacterial" post="pathogens (Reardon, 2020). Secondary Bacterial Infections Secondary bacterial infections"/>
  <result pre="fueling global growth of antibiotic resistant bacterial pathogens (Reardon, 2020)." exact="Secondary" post="Bacterial Infections Secondary bacterial infections develop in patients during"/>
  <result pre="global growth of antibiotic resistant bacterial pathogens (Reardon, 2020). Secondary" exact="Bacterial Infections" post="Secondary bacterial infections develop in patients during or after"/>
  <result pre="growth of antibiotic resistant bacterial pathogens (Reardon, 2020). Secondary Bacterial" exact="Infections" post="Secondary bacterial infections develop in patients during or after"/>
  <result pre="of antibiotic resistant bacterial pathogens (Reardon, 2020). Secondary Bacterial Infections" exact="Secondary" post="bacterial infections develop in patients during or after initial"/>
  <result pre="antibiotic resistant bacterial pathogens (Reardon, 2020). Secondary Bacterial Infections Secondary" exact="bacterial infections" post="develop in patients during or after initial infection with"/>
  <result pre="resistant bacterial pathogens (Reardon, 2020). Secondary Bacterial Infections Secondary bacterial" exact="infections" post="develop in patients during or after initial infection with"/>
  <result pre="Secondary bacterial infections develop in patients during or after initial" exact="infection" post="with an infective pathogen, often a virus (Morris et"/>
  <result pre="develop in patients during or after initial infection with an" exact="infective" post="pathogen, often a virus (Morris et al., 2017; Wang"/>
  <result pre="and mortality rates (Figure 1) (Mallia et al., 2012). Co-infections," exact="secondary" post="infections, or â€œsuperinfectionsâ€� occur during viral epidemics; around 50"/>
  <result pre="et al., 2012). Co-infections, secondary infections, or â€œsuperinfectionsâ€� occur during" exact="viral" post="epidemics; around 50 million deaths were ascribed to bacterial"/>
  <result pre="during viral epidemics; around 50 million deaths were ascribed to" exact="bacterial" post="co-infections during the 1918â€&quot;1919 Spanish Flu pandemic; although clinical"/>
  <result pre="Flu pandemic; although clinical records often do now record such" exact="infection" post="complications (Kash and Taubenberger, 2015; MacIntyre et al., 2018)."/>
  <result pre="complications (Kash and Taubenberger, 2015; MacIntyre et al., 2018). While" exact="secondary" post="infections occur in succession to the primary infection, co-infections"/>
  <result pre="(Kash and Taubenberger, 2015; MacIntyre et al., 2018). While secondary" exact="infections" post="occur in succession to the primary infection, co-infections are"/>
  <result pre="al., 2018). While secondary infections occur in succession to the" exact="primary" post="infection, co-infections are caused by multiple pathogens of viral,"/>
  <result pre="rather than a combination of pathogens, especially for the viralâ€&quot;bacterial" exact="infections" post="most commonly observed in patients (Jamieson et al., 2010)."/>
  <result pre="spp., are some of the most commonly isolated bacteria during" exact="secondary" post="infections (Handel et al., 2009). Hospitals are a common"/>
  <result pre="are some of the most commonly isolated bacteria during secondary" exact="infections" post="(Handel et al., 2009). Hospitals are a common source"/>
  <result pre="Hospitals are a common source of the pathogens that cause" exact="secondary" post="infections, these so-called nosocomial pathogen infections are acquired from"/>
  <result pre="the pathogens that cause secondary infections, these so-called nosocomial pathogen" exact="infections" post="are acquired from an environment in which antibiotics are"/>
  <result pre="that cause secondary infections, these so-called nosocomial pathogen infections are" exact="acquired" post="from an environment in which antibiotics are commonplace, and"/>
  <result pre="in which antibiotics are commonplace, and as such; many have" exact="acquired" post="resistance to a broad range of antibiotics. Decades of"/>
  <result pre="cases no (chemical) antibiotics exist to treat such infections, including" exact="secondary" post="infections. Secondary bacterial infections are facilitated by the exposure"/>
  <result pre="(chemical) antibiotics exist to treat such infections, including secondary infections." exact="Secondary" post="bacterial infections are facilitated by the exposure to a"/>
  <result pre="antibiotics exist to treat such infections, including secondary infections. Secondary" exact="bacterial infections" post="are facilitated by the exposure to a pathogen together"/>
  <result pre="exist to treat such infections, including secondary infections. Secondary bacterial" exact="infections" post="are facilitated by the exposure to a pathogen together"/>
  <result pre="react to both pathogen types, as a consequence of the" exact="primary" post="viral infection. For such patients, the only option is"/>
  <result pre="to both pathogen types, as a consequence of the primary" exact="viral infection." post="For such patients, the only option is to support"/>
  <result pre="to support their immune system and prevent progression of the" exact="infection" post="that could lead to the death of the patient"/>
  <result pre="could lead to the death of the patient such as" exact="septic shock." post="Antibiotics therapies deployed as a â€œlast resortâ€� or the"/>
  <result pre="Carbapenem-resistant Enterobacteriaceae (CRE), Colistin-resistant Klebsiella, Carbapenem-resistant Pseudomonas aeruginosa, and Carbapenem-resistant" exact="Acinetobacter" post="baumannii (Kumar and Chordia, 2017). The problem is exacerbated"/>
  <result pre="antibiotics (Loh and Leptihn, 2020). Other options to treat MDR" exact="infections" post="would be beneficial. FIGURE 1 Possible clinical progression of"/>
  <result pre="beneficial. FIGURE 1 Possible clinical progression of patients with a" exact="pulmonary" post="virus infection and prophylaxis or treatment options for bacterial"/>
  <result pre="FIGURE 1 Possible clinical progression of patients with a pulmonary" exact="virus infection" post="and prophylaxis or treatment options for bacterial secondary infections."/>
  <result pre="1 Possible clinical progression of patients with a pulmonary virus" exact="infection" post="and prophylaxis or treatment options for bacterial secondary infections."/>
  <result pre="a pulmonary virus infection and prophylaxis or treatment options for" exact="bacterial" post="secondary infections. Molecular Basis of Manifestation of Secondary Bacterial"/>
  <result pre="pulmonary virus infection and prophylaxis or treatment options for bacterial" exact="secondary" post="infections. Molecular Basis of Manifestation of Secondary Bacterial Infections"/>
  <result pre="options for bacterial secondary infections. Molecular Basis of Manifestation of" exact="Secondary" post="Bacterial Infections There are several hypotheses why secondary infections"/>
  <result pre="for bacterial secondary infections. Molecular Basis of Manifestation of Secondary" exact="Bacterial Infections" post="There are several hypotheses why secondary infections quickly establish"/>
  <result pre="bacterial secondary infections. Molecular Basis of Manifestation of Secondary Bacterial" exact="Infections" post="There are several hypotheses why secondary infections quickly establish"/>
  <result pre="Manifestation of Secondary Bacterial Infections There are several hypotheses why" exact="secondary" post="infections quickly establish in patients with a pulmonary viral"/>
  <result pre="of Secondary Bacterial Infections There are several hypotheses why secondary" exact="infections" post="quickly establish in patients with a pulmonary viral infection,"/>
  <result pre="hypotheses why secondary infections quickly establish in patients with a" exact="pulmonary" post="viral infection, including immunological host changes, mechanical damage and"/>
  <result pre="why secondary infections quickly establish in patients with a pulmonary" exact="viral infection," post="including immunological host changes, mechanical damage and diffusion, and"/>
  <result pre="and removal of mucus within the lungs. Much of how" exact="secondary" post="infections manifest themselves and what role the immune response"/>
  <result pre="removal of mucus within the lungs. Much of how secondary" exact="infections" post="manifest themselves and what role the immune response to"/>
  <result pre="against a prokaryotic pathogen, is poorly understood. The prevalence of" exact="secondary" post="bacterial infections during a primary virus disease is due"/>
  <result pre="a prokaryotic pathogen, is poorly understood. The prevalence of secondary" exact="bacterial infections" post="during a primary virus disease is due to the"/>
  <result pre="prokaryotic pathogen, is poorly understood. The prevalence of secondary bacterial" exact="infections" post="during a primary virus disease is due to the"/>
  <result pre="poorly understood. The prevalence of secondary bacterial infections during a" exact="primary" post="virus disease is due to the altered immune response"/>
  <result pre="The prevalence of secondary bacterial infections during a primary virus" exact="disease" post="is due to the altered immune response to one"/>
  <result pre="often changes the response of the system to the other" exact="infectious" post="agent (here: the bacterium), resulting in increased morbidity (Hendaus"/>
  <result pre="the bacterium), resulting in increased morbidity (Hendaus et al., 2015)." exact="Severe" post="viral infections initiate changes in the immune response of"/>
  <result pre="bacterium), resulting in increased morbidity (Hendaus et al., 2015). Severe" exact="viral" post="infections initiate changes in the immune response of the"/>
  <result pre="resulting in increased morbidity (Hendaus et al., 2015). Severe viral" exact="infections" post="initiate changes in the immune response of the host"/>
  <result pre="Roquilly et al., 2017; Morgan et al., 2018). In addition," exact="viral" post="infections of the respiratory system can lead to immune"/>
  <result pre="et al., 2017; Morgan et al., 2018). In addition, viral" exact="infections" post="of the respiratory system can lead to immune responses"/>
  <result pre="Morgan et al., 2018). In addition, viral infections of the" exact="respiratory" post="system can lead to immune responses that alter the"/>
  <result pre="has been suggested to possibly modulate immune cell priming against" exact="secondary" post="bacterial challenge (Hanada et al., 2018). In most cases,"/>
  <result pre="been suggested to possibly modulate immune cell priming against secondary" exact="bacterial" post="challenge (Hanada et al., 2018). In most cases, epithelial"/>
  <result pre="secondary bacterial challenge (Hanada et al., 2018). In most cases," exact="epithelial" post="cells are damaged during the primary viral infection, impeding"/>
  <result pre="2018). In most cases, epithelial cells are damaged during the" exact="primary" post="viral infection, impeding mucociliary clearance that leads to an"/>
  <result pre="In most cases, epithelial cells are damaged during the primary" exact="viral infection," post="impeding mucociliary clearance that leads to an accumulation of"/>
  <result pre="of mucus (Perry et al., 2005). Bacteria are able to" exact="diffuse" post="into the mucus but thickened dense mucus impedes penetration"/>
  <result pre="but thickened dense mucus impedes penetration of host immune cells." exact="Secondary" post="bacterial infections are also facilitated by the immune response"/>
  <result pre="thickened dense mucus impedes penetration of host immune cells. Secondary" exact="bacterial infections" post="are also facilitated by the immune response of the"/>
  <result pre="dense mucus impedes penetration of host immune cells. Secondary bacterial" exact="infections" post="are also facilitated by the immune response of the"/>
  <result pre="facilitated by the immune response of the host to a" exact="viral" post="attack. One of the more important factors seems to"/>
  <result pre="immunosuppression of the host innate immune response initiated by the" exact="viral infection" post="which facilitates opportunistic bacteria, like Streptococcus to infect the"/>
  <result pre="of the host innate immune response initiated by the viral" exact="infection" post="which facilitates opportunistic bacteria, like Streptococcus to infect the"/>
  <result pre="et al., 2011). Cells of a host suffering from a" exact="viral infection" post="are more susceptible to bacterial attachment and colonization (Pittet"/>
  <result pre="al., 2011). Cells of a host suffering from a viral" exact="infection" post="are more susceptible to bacterial attachment and colonization (Pittet"/>
  <result pre="host suffering from a viral infection are more susceptible to" exact="bacterial" post="attachment and colonization (Pittet et al., 2010; Nyangacha et"/>
  <result pre="et al., 2017). Many viruses, including influenza virus, rhinovirus, and" exact="respiratory" post="syncytial virus (RSV), have detrimental effects on the mucosal"/>
  <result pre="virus (RSV), have detrimental effects on the mucosal layer facilitating" exact="bacterial" post="adherence of, e.g., S. pneumoniae, P. aeruginosa, and H."/>
  <result pre="on the linings of the lungs (Morris, 2007). For some" exact="pulmonary" post="viruses such as influenza, Toll-like receptor (TLR) pathways are"/>
  <result pre="which results in an increase of attachment of bacteria to" exact="epithelial" post="cells (Kurt-Jones et al., 2000; Haynes et al., 2001)."/>
  <result pre="TLR and RIG-I-like receptor activation results in the production of" exact="Type I" post="Interferon, changing the inflammatory response to TLR ligands, e.g.,"/>
  <result pre="I Interferon, changing the inflammatory response to TLR ligands, e.g.," exact="bacterial" post="lipopolysaccharide (Doughty et al., 2001; Nansen and Thomsen, 2001)."/>
  <result pre="immune response combined with accessible routes of entry for the" exact="bacterial" post="pathogen(s). For patients with viralâ€&quot;bacterial infections, the availability of"/>
  <result pre="with viralâ€&quot;bacterial infections, the availability of therapeutic options for both" exact="infectious" post="agents is crucial. Antivirals are deployed to combat the"/>
  <result pre="to combat the virus, which have no effect on the" exact="bacterial" post="pathogens (McCullers, 2011), and bacterial infections are treated with"/>
  <result pre="have no effect on the bacterial pathogens (McCullers, 2011), and" exact="bacterial infections" post="are treated with antibiotics, or such small-molecule compounds to"/>
  <result pre="no effect on the bacterial pathogens (McCullers, 2011), and bacterial" exact="infections" post="are treated with antibiotics, or such small-molecule compounds to"/>
  <result pre="with antibiotics, or such small-molecule compounds to try and prevent" exact="secondary" post="infections. Broad-spectrum antibiotic may result in undesirable inflammatory responses"/>
  <result pre="2002; Mahar et al., 2014). To prevent complications caused by" exact="secondary" post="bacterial infections and to eliminate bacterial pathogens, alternative antibacterial"/>
  <result pre="Mahar et al., 2014). To prevent complications caused by secondary" exact="bacterial infections" post="and to eliminate bacterial pathogens, alternative antibacterial therapies are"/>
  <result pre="et al., 2014). To prevent complications caused by secondary bacterial" exact="infections" post="and to eliminate bacterial pathogens, alternative antibacterial therapies are"/>
  <result pre="prevent complications caused by secondary bacterial infections and to eliminate" exact="bacterial" post="pathogens, alternative antibacterial therapies are needed. Coronavirus, Pneumonia, Antibiotics,"/>
  <result pre="alternative antibacterial therapies are needed. Coronavirus, Pneumonia, Antibiotics, and Antibiotic" exact="Resistance" post="Some of the most significant outbreaks, epidemics, and global"/>
  <result pre="and global pandemics, with high morbidities and mortality are from" exact="viral" post="respiratory infections caused by influenza virus or CoV species;"/>
  <result pre="global pandemics, with high morbidities and mortality are from viral" exact="respiratory" post="infections caused by influenza virus or CoV species; for"/>
  <result pre="pandemics, with high morbidities and mortality are from viral respiratory" exact="infections" post="caused by influenza virus or CoV species; for which"/>
  <result pre="virus or CoV species; for which treatment is compromised by" exact="secondary" post="bacterial infections (Yang et al., 2020; Zhou et al.,"/>
  <result pre="or CoV species; for which treatment is compromised by secondary" exact="bacterial infections" post="(Yang et al., 2020; Zhou et al., 2020). While"/>
  <result pre="CoV species; for which treatment is compromised by secondary bacterial" exact="infections" post="(Yang et al., 2020; Zhou et al., 2020). While"/>
  <result pre="(Yang et al., 2020; Zhou et al., 2020). While a" exact="viral infection" post="alone can be detrimental to a patient, the pathogen"/>
  <result pre="et al., 2020; Zhou et al., 2020). While a viral" exact="infection" post="alone can be detrimental to a patient, the pathogen"/>
  <result pre="can be detrimental to a patient, the pathogen that exasperates" exact="disease" post="progression is most commonly of bacterial origin (Yang et"/>
  <result pre="the pathogen that exasperates disease progression is most commonly of" exact="bacterial" post="origin (Yang et al., 2020). During the 2009 H1N1"/>
  <result pre="between 29 and 55% of fatal cases were caused by" exact="secondary" post="bacterial infections (Center for Disease Control and Prevention, 2012)."/>
  <result pre="29 and 55% of fatal cases were caused by secondary" exact="bacterial infections" post="(Center for Disease Control and Prevention, 2012). During the"/>
  <result pre="and 55% of fatal cases were caused by secondary bacterial" exact="infections" post="(Center for Disease Control and Prevention, 2012). During the"/>
  <result pre="fatal cases were caused by secondary bacterial infections (Center for" exact="Disease" post="Control and Prevention, 2012). During the ongoing COVID-19 pandemic,"/>
  <result pre="pandemic, around 15% of hospital cases have been associated with" exact="secondary" post="bacterial pathogens, and 50% of patients died (Zhou et"/>
  <result pre="around 15% of hospital cases have been associated with secondary" exact="bacterial" post="pathogens, and 50% of patients died (Zhou et al.,"/>
  <result pre="COVID-19 have developed high rates of up to 50% of" exact="secondary" post="bacterial infections leading to secondary bacterial pneumonia. Half of"/>
  <result pre="have developed high rates of up to 50% of secondary" exact="bacterial infections" post="leading to secondary bacterial pneumonia. Half of COVID-19 fatalities"/>
  <result pre="developed high rates of up to 50% of secondary bacterial" exact="infections" post="leading to secondary bacterial pneumonia. Half of COVID-19 fatalities"/>
  <result pre="of up to 50% of secondary bacterial infections leading to" exact="secondary" post="bacterial pneumonia. Half of COVID-19 fatalities experienced some form"/>
  <result pre="up to 50% of secondary bacterial infections leading to secondary" exact="bacterial pneumonia." post="Half of COVID-19 fatalities experienced some form of secondary"/>
  <result pre="bacterial pneumonia. Half of COVID-19 fatalities experienced some form of" exact="secondary" post="infection (pulmonary or other) that may have contributed to"/>
  <result pre="pneumonia. Half of COVID-19 fatalities experienced some form of secondary" exact="infection" post="(pulmonary or other) that may have contributed to their"/>
  <result pre="that may have contributed to their death. During severe COVID-19" exact="disease" post="with pneumonia, the air sacs of the lungs fill"/>
  <result pre="destroying surrounding cells. The frequency (30â€&quot;40%) of complications due to" exact="bacterial" post="involvement was significantly higher in fatal COVID-19 patients than"/>
  <result pre="fatal COVID-19 cases, death is most frequently a result of" exact="respiratory" post="failure from severe pneumonia, caused either by SARS-CoV-2 itself"/>
  <result pre="either by SARS-CoV-2 itself or as a result of a" exact="secondary" post="bacterial infection (Tetro, 2020). Patients suffering of a pulmonary"/>
  <result pre="by SARS-CoV-2 itself or as a result of a secondary" exact="bacterial infection" post="(Tetro, 2020). Patients suffering of a pulmonary virus infection,"/>
  <result pre="SARS-CoV-2 itself or as a result of a secondary bacterial" exact="infection" post="(Tetro, 2020). Patients suffering of a pulmonary virus infection,"/>
  <result pre="a secondary bacterial infection (Tetro, 2020). Patients suffering of a" exact="pulmonary" post="virus infection, including COVID-19, are often administered prophylactic antibiotics,"/>
  <result pre="secondary bacterial infection (Tetro, 2020). Patients suffering of a pulmonary" exact="virus infection," post="including COVID-19, are often administered prophylactic antibiotics, including azithromycin,"/>
  <result pre="moxifloxacin, ceftriaxone, vancomycin, or cefepime, to reduce the risk of" exact="secondary" post="infections; often in addition to another antibiotic that is"/>
  <result pre="in addition to another antibiotic that is deployed once the" exact="infection" post="is identified (Holshue et al., 2020; Wang et al.,"/>
  <result pre="2020; Wang et al., 2020). As the numbers of antibiotic-resistant" exact="bacterial" post="strains continue to grow, there is increased the risk"/>
  <result pre="patients have been reported, but mainly these focus on the" exact="viral infection" post="itself. There are few reports detailing secondary bacterial infections"/>
  <result pre="have been reported, but mainly these focus on the viral" exact="infection" post="itself. There are few reports detailing secondary bacterial infections"/>
  <result pre="on the viral infection itself. There are few reports detailing" exact="secondary" post="bacterial infections and even less describing AMR. Until a"/>
  <result pre="the viral infection itself. There are few reports detailing secondary" exact="bacterial infections" post="and even less describing AMR. Until a vaccine is"/>
  <result pre="viral infection itself. There are few reports detailing secondary bacterial" exact="infections" post="and even less describing AMR. Until a vaccine is"/>
  <result pre="even less describing AMR. Until a vaccine is deployed globally," exact="bacterial" post="secondary infections will continue to be important in COVID-19"/>
  <result pre="less describing AMR. Until a vaccine is deployed globally, bacterial" exact="secondary" post="infections will continue to be important in COVID-19 clinical"/>
  <result pre="describing AMR. Until a vaccine is deployed globally, bacterial secondary" exact="infections" post="will continue to be important in COVID-19 clinical care."/>
  <result pre="COVID-19 clinical care. New antibiotics or alternative treatments targeted against" exact="secondary" post="bacterial infections need to be developed for COVID-19 and"/>
  <result pre="clinical care. New antibiotics or alternative treatments targeted against secondary" exact="bacterial infections" post="need to be developed for COVID-19 and subsequent pandemics."/>
  <result pre="care. New antibiotics or alternative treatments targeted against secondary bacterial" exact="infections" post="need to be developed for COVID-19 and subsequent pandemics."/>
  <result pre="COVID-19 and subsequent pandemics. Antibacterial Therapy in Patients With Non-bacterial" exact="Primary" post="Infections To reduce the risk of superinfections, cases of"/>
  <result pre="and subsequent pandemics. Antibacterial Therapy in Patients With Non-bacterial Primary" exact="Infections" post="To reduce the risk of superinfections, cases of pneumonia"/>
  <result pre="Primary Infections To reduce the risk of superinfections, cases of" exact="pneumonia" post="caused by respiratory viruses including SARS-CoV-2 are often prophylactically"/>
  <result pre="reduce the risk of superinfections, cases of pneumonia caused by" exact="respiratory" post="viruses including SARS-CoV-2 are often prophylactically treated with antibiotics"/>
  <result pre="bacteria. The alternative, i.e., no prophylactic treatment, often results in" exact="bacterial infections," post="in principle, demonstrating the effectiveness of this strategy. Prophylactic"/>
  <result pre="crisis and is ineffective when patients acquire antibiotic-resistant strainsâ€&quot;nosocomial hospital-acquired" exact="infections" post="are commonly observed for ICU patients infected with a"/>
  <result pre="infections are commonly observed for ICU patients infected with a" exact="respiratory" post="virus (Zhou et al., 2020). Nosocomial infections are becoming"/>
  <result pre="infected with a respiratory virus (Zhou et al., 2020). Nosocomial" exact="infections" post="are becoming more common due to the rise of"/>
  <result pre="are becoming more common due to the rise of resistant" exact="bacterial" post="pathogens. Alternative antibacterial therapeutic strategies are needed; such as"/>
  <result pre="or phage-derived therapeutic proteins. Phage Therapy and Phage-Based Strategies During" exact="Viral" post="Epidemics An alternative approach to treating secondary bacterial infections,"/>
  <result pre="Phage-Based Strategies During Viral Epidemics An alternative approach to treating" exact="secondary" post="bacterial infections, especially AMR pathogens, is the application of"/>
  <result pre="Strategies During Viral Epidemics An alternative approach to treating secondary" exact="bacterial infections," post="especially AMR pathogens, is the application of phage therapy;"/>
  <result pre="using microbial viruses to kill their host, ideally clearing the" exact="bacterial infection" post="(Altamirano and Barr, 2019). Bacteriophages are naturally occurring viruses"/>
  <result pre="microbial viruses to kill their host, ideally clearing the bacterial" exact="infection" post="(Altamirano and Barr, 2019). Bacteriophages are naturally occurring viruses"/>
  <result pre="envelope of the cell, forming a channel through which the" exact="viral" post="genome is translocated into the cytoplasm of the bacterium"/>
  <result pre="of chemical antibiotics, endolysins, and bacteriophages in the treatment of" exact="bacterial infections." post="A major advantage of phages is that they exhibit"/>
  <result pre="infections. A major advantage of phages is that they exhibit" exact="bacterial" post="host specificity (Seguin et al., 2006) and selectively target"/>
  <result pre="even strain-specific, infecting and killing their target bacterium. As most" exact="secondary" post="bacterial infections are caused by one bacterial genus, species"/>
  <result pre="strain-specific, infecting and killing their target bacterium. As most secondary" exact="bacterial infections" post="are caused by one bacterial genus, species or strain,"/>
  <result pre="infecting and killing their target bacterium. As most secondary bacterial" exact="infections" post="are caused by one bacterial genus, species or strain,"/>
  <result pre="bacterium. As most secondary bacterial infections are caused by one" exact="bacterial" post="genus, species or strain, phage therapy offers a promising"/>
  <result pre="Clinical studies using phages have demonstrated success at eliminating resistant" exact="bacterial" post="strains (Capparelli et al., 2007; Kutter et al., 2010;"/>
  <result pre="interact with human cells and are not able to cause" exact="infections" post="in humans (Barr, 2019; Van Belleghem et al., 2019)."/>
  <result pre="the liver and might result in organ failure. Since most" exact="secondary" post="bacterial infections occur in immunocompromised or immunodeficient patients, it"/>
  <result pre="liver and might result in organ failure. Since most secondary" exact="bacterial infections" post="occur in immunocompromised or immunodeficient patients, it is necessary"/>
  <result pre="and might result in organ failure. Since most secondary bacterial" exact="infections" post="occur in immunocompromised or immunodeficient patients, it is necessary"/>
  <result pre="efficacy of phage therapy under such conditions. Previous studies on" exact="cancer" post="patients and renal allograft patients showed that phage therapy"/>
  <result pre="patients showed that phage therapy can be effective in treating" exact="secondary" post="bacterial infections and co-infections (Weber-Dabrowska et al., 2001; MiÈ©dzybrodzki"/>
  <result pre="showed that phage therapy can be effective in treating secondary" exact="bacterial infections" post="and co-infections (Weber-Dabrowska et al., 2001; MiÈ©dzybrodzki et al.,"/>
  <result pre="that phage therapy can be effective in treating secondary bacterial" exact="infections" post="and co-infections (Weber-Dabrowska et al., 2001; MiÈ©dzybrodzki et al.,"/>
  <result pre="lack of evidence showing the efficacy of phage therapy during" exact="viral" post="infections, bacteriophages have been shown to be effective prophylactic"/>
  <result pre="bacteria, such as the alteration in phage receptors on the" exact="bacterial" post="cell surface; degradation of phage DNA by restriction endonuclease"/>
  <result pre="of mechanisms inhibiting the penetration of phage DNA into the" exact="bacterial" post="host, among others (Jo et al., 2016b; ValÃ©rio et"/>
  <result pre="phages and antibiotics is expected to provide stronger suppression of" exact="bacterial" post="growth and is expected to help reduce bacterial resistance"/>
  <result pre="suppression of bacterial growth and is expected to help reduce" exact="bacterial" post="resistance against phages and antibiotics (different targets are used"/>
  <result pre="studies have shown improved efficacy in controlling the growth of" exact="bacterial" post="pathogens such as Pseudomonas fluorescens, Pseudomonas aeruginosa, Escherichia coli,"/>
  <result pre="to have higher success rates in preventing the emergence of" exact="bacterial" post="resistance as bacteria that become non-susceptible to one agent"/>
  <result pre="versa. Phage-antibiotic therapy can prevent the emergence of double resistant" exact="bacterial" post="mutants, as a bacterium is unlikely to acquire phage"/>
  <result pre="2018; Tagliaferri et al., 2019). Phage-antibiotic combinations that have different" exact="bacterial" post="targets can assist in enhanced bacterial inactivation. The use"/>
  <result pre="combinations that have different bacterial targets can assist in enhanced" exact="bacterial" post="inactivation. The use of sub-lethal concentrations (concentration of antibiotics"/>
  <result pre="bacterial inactivation. The use of sub-lethal concentrations (concentration of antibiotics" exact="lower" post="than minimal inhibitory concentrations) of antibiotics can enhance phage"/>
  <result pre="concentrations) of antibiotics can enhance phage productivity mediating phage induced" exact="bacterial" post="decline (Tagliaferri et al., 2019), known as phage-antibiotic synergy."/>
  <result pre="phage-antibiotic synergy. One factor proposed responsible for phage-antibiotic synergy is" exact="bacterial" post="elongation or filamentation induced by sub-lethal concentrations of antibiotics"/>
  <result pre="different inhibitory mechanisms, they often result in the blocking of" exact="bacterial" post="cell division causing elongation of the bacterial cell, as"/>
  <result pre="the blocking of bacterial cell division causing elongation of the" exact="bacterial" post="cell, as a large bacterial surface area is available"/>
  <result pre="division causing elongation of the bacterial cell, as a large" exact="bacterial" post="surface area is available for phage attachment, bacterial cells"/>
  <result pre="a large bacterial surface area is available for phage attachment," exact="bacterial" post="cells are vulnerable toward phage infection, increasing the efficacy"/>
  <result pre="stimulate virulent phage production, together with the changes induced in" exact="bacterial" post="membrane proteins by antibiotics and may enhance the lytic"/>
  <result pre="necessary higher doses of the antibiotic (Knezevic et al., 2013)." exact="Infections" post="caused by biofilm-forming bacteria, especially nosocomial infections, are difficult"/>
  <result pre="(Knezevic et al., 2013). Infections caused by biofilm-forming bacteria, especially" exact="nosocomial infections," post="are difficult to treat using antibiotics (Pires et al.,"/>
  <result pre="using antibiotics (Pires et al., 2017). The emergence of ventilator-associated" exact="secondary" post="pneumonia is often due to biofilm forming bacteria such"/>
  <result pre="antibiotics (Pires et al., 2017). The emergence of ventilator-associated secondary" exact="pneumonia" post="is often due to biofilm forming bacteria such as"/>
  <result pre="antibiotic, can increase the susceptibility of bacteria and reduce plasmid-borne" exact="bacterial" post="resistance by targeting plasmid bearing bacteria in the biofilm"/>
  <result pre="plasmid bearing bacteria in the biofilm (Å�usiak-Szelachowska et al., 2020)." exact="Combined" post="phage and antibiotic therapy with a sequential approach of"/>
  <result pre="penetrate into deeper layers of the biofilm, replicating in the" exact="lower" post="layers and facilitating the destruction of the biofilm (Å�usiak-Szelachowska"/>
  <result pre="al., 2020). Antibiotics administered following biofilm treatment by phages enhance" exact="bacterial" post="reduction Akturk et al., 2019. Phage Endolysins as Antibacterial"/>
  <result pre="into the environment, degrading the peptidoglycan layer of the host" exact="bacterial" post="cell wall (Imanishi et al., 2019). The ability of"/>
  <result pre="et al., 2019). The ability of endolysins to digest the" exact="bacterial" post="cell wall when applied exogenously offers the opportunity for"/>
  <result pre="are low since endolysins target cell wall molecules essential for" exact="bacterial" post="viability (Å�usiak-Szelachowska et al., 2020). Phage-derived endolysins are promising"/>
  <result pre="et al., 2020). Phage-derived endolysins are promising candidates for treating" exact="secondary" post="bacterial infections or multi-drug resistant infections (Imanishi et al.,"/>
  <result pre="al., 2020). Phage-derived endolysins are promising candidates for treating secondary" exact="bacterial infections" post="or multi-drug resistant infections (Imanishi et al., 2019; Kim"/>
  <result pre="2020). Phage-derived endolysins are promising candidates for treating secondary bacterial" exact="infections" post="or multi-drug resistant infections (Imanishi et al., 2019; Kim"/>
  <result pre="promising candidates for treating secondary bacterial infections or multi-drug resistant" exact="infections" post="(Imanishi et al., 2019; Kim et al., 2020). There"/>
  <result pre="endolysins have been reported, including use in biocontrol agents against" exact="bacterial" post="pathogens in food and agricultural industries (Matamp and Bhat,"/>
  <result pre="de Wit et al., 2019). Most naturally occurring endolysins have" exact="limited" post="effect on Gram-negative bacteria as the outer membrane (OM)"/>
  <result pre="of the long sugar chains and are directly cross-linked by" exact="short" post="interpeptide bridges (black solid line) via the third residue"/>
  <result pre="therapy has been successful in treating: (i) MDR A. baumannii" exact="infections" post="(Schooley et al., 2017); (ii) against Mycobacterial infections (Dedrick"/>
  <result pre="A. baumannii infections (Schooley et al., 2017); (ii) against Mycobacterial" exact="infections" post="(Dedrick et al., 2019); (iii) burn-wound infections caused by"/>
  <result pre="(ii) against Mycobacterial infections (Dedrick et al., 2019); (iii) burn-wound" exact="infections" post="caused by P. aeruginosa (Jault et al., 2019); (iv)"/>
  <result pre="infections caused by P. aeruginosa (Jault et al., 2019); (iv)" exact="infections" post="caused by S. aureus (Fabijan et al., 2020); (v)"/>
  <result pre="caused by S. aureus (Fabijan et al., 2020); (v) Enterococcal" exact="infections" post="(Khalifa et al., 2016); and (vi) against MDR E."/>
  <result pre="(Khalifa et al., 2016); and (vi) against MDR E. coli" exact="infections" post="(Sarker et al., 2016; Kakasis and Panitsa, 2019). Preparations"/>
  <result pre="Phages With the looming crisis of increasing numbers of MDR" exact="bacterial infections," post="alternatives to chemical antibiotics are urgently needed. To prevent"/>
  <result pre="infections, alternatives to chemical antibiotics are urgently needed. To prevent" exact="secondary" post="bacterial infections, prophylactic use of phages could be applied"/>
  <result pre="alternatives to chemical antibiotics are urgently needed. To prevent secondary" exact="bacterial infections," post="prophylactic use of phages could be applied similar to"/>
  <result pre="targets a broad range of pathogenic species likely to cause" exact="bacterial pneumonia." post="Since phages are highly specific, a phage cocktail would"/>
  <result pre="making deployment of phages as prophylactics in patients infected with" exact="pulmonary" post="viruses, complex. Phage-derived therapeutic proteins such as endolysins would"/>
  <result pre="as endolysins would be advantageous as they would have a" exact="lower" post="specificity toward bacteria and be able to inactivate a"/>
  <result pre="bacteria and be able to inactivate a broader range of" exact="bacterial" post="pathogens. Phages can also be used as therapeutic agents"/>
  <result pre="can also be used as therapeutic agents for an established" exact="bacterial infection." post="Due to the high specificity of phages, phage therapy"/>
  <result pre="with antibiotics or alone. Limitations of phage therapy in treating" exact="secondary" post="bacterial infections include: the preparation of therapeutic cGMP (Good"/>
  <result pre="antibiotics or alone. Limitations of phage therapy in treating secondary" exact="bacterial infections" post="include: the preparation of therapeutic cGMP (Good Manufacturing Practice)"/>
  <result pre="or alone. Limitations of phage therapy in treating secondary bacterial" exact="infections" post="include: the preparation of therapeutic cGMP (Good Manufacturing Practice)"/>
  <result pre="phages; patient acceptance, and possibly, adverse immune responses leading to" exact="primary" post="treatment failure. Conclusion Secondary bacterial infections play a critical"/>
  <result pre="possibly, adverse immune responses leading to primary treatment failure. Conclusion" exact="Secondary" post="bacterial infections play a critical role in the morbidity"/>
  <result pre="adverse immune responses leading to primary treatment failure. Conclusion Secondary" exact="bacterial infections" post="play a critical role in the morbidity and mortality"/>
  <result pre="immune responses leading to primary treatment failure. Conclusion Secondary bacterial" exact="infections" post="play a critical role in the morbidity and mortality"/>
  <result pre="morbidity and mortality rates of patients initially falling ill with" exact="pulmonary" post="viral diseases. Evidence from the current SARS-CoV-2 pandemic shows"/>
  <result pre="and mortality rates of patients initially falling ill with pulmonary" exact="viral" post="diseases. Evidence from the current SARS-CoV-2 pandemic shows that"/>
  <result pre="Evidence from the current SARS-CoV-2 pandemic shows that the antibiotic-resistant" exact="bacterial infections" post="are a significant threat to hospitalized COVID-19 patients. Nosocomial"/>
  <result pre="from the current SARS-CoV-2 pandemic shows that the antibiotic-resistant bacterial" exact="infections" post="are a significant threat to hospitalized COVID-19 patients. Nosocomial"/>
  <result pre="infections are a significant threat to hospitalized COVID-19 patients. Nosocomial" exact="infections" post="including ventilator-associated infections are often unavoidable and especially so"/>
  <result pre="significant threat to hospitalized COVID-19 patients. Nosocomial infections including ventilator-associated" exact="infections" post="are often unavoidable and especially so during a pandemic,"/>
  <result pre="therapy is one of the most promising options for treating" exact="secondary" post="bacterial infections. Phage therapy either as a stand-alone treatment"/>
  <result pre="is one of the most promising options for treating secondary" exact="bacterial infections." post="Phage therapy either as a stand-alone treatment or in"/>
  <result pre="combination with antibiotics may offer a valuable alternative for treating" exact="secondary" post="bacterial infections. Clinical studies should evaluate the efficacy of"/>
  <result pre="with antibiotics may offer a valuable alternative for treating secondary" exact="bacterial infections." post="Clinical studies should evaluate the efficacy of phage therapy"/>
  <result pre="application of phage products, such as endolysins, should be investigated." exact="Pulmonary" post="CoVs will likely be a clinical challenge for many"/>
  <result pre="likely be a clinical challenge for many years to come." exact="Viral" post="pandemics from CoVs and emerging pathogens are inevitable in"/>
  <result pre="the next pandemic, exploring and establishing new avenues to treat" exact="bacterial" post="pathogens commonly observed in secondary infections. To avert an"/>
  <result pre="establishing new avenues to treat bacterial pathogens commonly observed in" exact="secondary" post="infections. To avert an emerging healthcare crisis due from"/>
  <result pre="an emerging healthcare crisis due from COVID-1 and antibiotic-resistance of" exact="secondary" post="infections; medical interventions employing phage products or phage therapy"/>
  <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
  <result pre="antibacterials against Gram-negative bacteria.Future Microbiol.10377â€&quot;390. 10.2217/fmb.15.825812461 BrookI. (1995). Microbiology of" exact="secondary" post="bacterial infection in scabies lesions.J. Clin. Microbiol.332139â€&quot;2140. 10.1128/jcm.33.8.2139-2140.19957559963 BrookI."/>
  <result pre="against Gram-negative bacteria.Future Microbiol.10377â€&quot;390. 10.2217/fmb.15.825812461 BrookI. (1995). Microbiology of secondary" exact="bacterial infection" post="in scabies lesions.J. Clin. Microbiol.332139â€&quot;2140. 10.1128/jcm.33.8.2139-2140.19957559963 BrookI. (2002). Secondary"/>
  <result pre="Gram-negative bacteria.Future Microbiol.10377â€&quot;390. 10.2217/fmb.15.825812461 BrookI. (1995). Microbiology of secondary bacterial" exact="infection" post="in scabies lesions.J. Clin. Microbiol.332139â€&quot;2140. 10.1128/jcm.33.8.2139-2140.19957559963 BrookI. (2002). Secondary"/>
  <result pre="Microbiol.10377â€&quot;390. 10.2217/fmb.15.825812461 BrookI. (1995). Microbiology of secondary bacterial infection in" exact="scabies" post="lesions.J. Clin. Microbiol.332139â€&quot;2140. 10.1128/jcm.33.8.2139-2140.19957559963 BrookI. (2002). Secondary bacterial infections"/>
  <result pre="bacterial infection in scabies lesions.J. Clin. Microbiol.332139â€&quot;2140. 10.1128/jcm.33.8.2139-2140.19957559963 BrookI. (2002)." exact="Secondary" post="bacterial infections complicating skin lesions.J. Med. Microbiol.51808â€&quot;812. 10.1099/0022-1317-51-10-80812435058 BrÃ¼ssowH."/>
  <result pre="infection in scabies lesions.J. Clin. Microbiol.332139â€&quot;2140. 10.1128/jcm.33.8.2139-2140.19957559963 BrookI. (2002). Secondary" exact="bacterial infections" post="complicating skin lesions.J. Med. Microbiol.51808â€&quot;812. 10.1099/0022-1317-51-10-80812435058 BrÃ¼ssowH. (2005). Phage"/>
  <result pre="in scabies lesions.J. Clin. Microbiol.332139â€&quot;2140. 10.1128/jcm.33.8.2139-2140.19957559963 BrookI. (2002). Secondary bacterial" exact="infections" post="complicating skin lesions.J. Med. Microbiol.51808â€&quot;812. 10.1099/0022-1317-51-10-80812435058 BrÃ¼ssowH. (2005). Phage"/>
  <result pre="Staphylococcus aureus in mice.Antimicrob. Agents Chemother.512765â€&quot;2773. 10.1128/aac.01513-0617517843 collab: Center for" exact="Disease" post="Control and Prevention (2012). Available online at: https://www.cdc.gov/flu/spotlights/pandemic-global-estimates.htm(accessed June"/>
  <result pre="bacteria and their phage foes.Nature577327â€&quot;336. 10.1038/s41586-019-1894-831942051 HanadaS.PirzadehM.CarverK. Y.DengJ. C. (2018)." exact="Respiratory" post="viral infection-induced Microbiome alterations and secondary bacterial pneumonia.Front. Immunol.9:2640."/>
  <result pre="and their phage foes.Nature577327â€&quot;336. 10.1038/s41586-019-1894-831942051 HanadaS.PirzadehM.CarverK. Y.DengJ. C. (2018). Respiratory" exact="viral" post="infection-induced Microbiome alterations and secondary bacterial pneumonia.Front. Immunol.9:2640. 10.3389/fimmu.2018.0264030505304"/>
  <result pre="HanadaS.PirzadehM.CarverK. Y.DengJ. C. (2018). Respiratory viral infection-induced Microbiome alterations and" exact="secondary" post="bacterial pneumonia.Front. Immunol.9:2640. 10.3389/fimmu.2018.0264030505304 HandelA.LonginiI. M.AntiaR. (2009). Intervention strategies"/>
  <result pre="Y.DengJ. C. (2018). Respiratory viral infection-induced Microbiome alterations and secondary" exact="bacterial" post="pneumonia.Front. Immunol.9:2640. 10.3389/fimmu.2018.0264030505304 HandelA.LonginiI. M.AntiaR. (2009). Intervention strategies for"/>
  <result pre="(2009). Intervention strategies for an influenza pandemic taking into account" exact="secondary" post="bacterial infections.Epidem1185â€&quot;195. 10.1016/j.epidem.2009.09.00120161493 HaynesL. M.MooreD. D.Kurt-JonesE. A.FinbergR. W.AndersonL. J.TrippR."/>
  <result pre="Intervention strategies for an influenza pandemic taking into account secondary" exact="bacterial" post="infections.Epidem1185â€&quot;195. 10.1016/j.epidem.2009.09.00120161493 HaynesL. M.MooreD. D.Kurt-JonesE. A.FinbergR. W.AndersonL. J.TrippR. A."/>
  <result pre="(2001). Involvement of toll-like receptor 4 in innate immunity to" exact="respiratory" post="syncytial virus.J. Virol.7510730â€&quot;10737. 10.1128/jvi.75.22.10730-10737.200111602714 HendausM. A.JomhaF. A.AlhammadiA. H. (2015)."/>
  <result pre="syncytial virus.J. Virol.7510730â€&quot;10737. 10.1128/jvi.75.22.10730-10737.200111602714 HendausM. A.JomhaF. A.AlhammadiA. H. (2015). Virus-induced" exact="secondary" post="bacterial infection: a concise review.Ther. Clin. Risk Manag.111265â€&quot;1271.26345407 HolshueM."/>
  <result pre="virus.J. Virol.7510730â€&quot;10737. 10.1128/jvi.75.22.10730-10737.200111602714 HendausM. A.JomhaF. A.AlhammadiA. H. (2015). Virus-induced secondary" exact="bacterial" post="infection: a concise review.Ther. Clin. Risk Manag.111265â€&quot;1271.26345407 HolshueM. L.DeBoltC.LindquistS.LofyK."/>
  <result pre="Article influenza virus-induced glucocorticoids compromise innate host defense against a" exact="secondary" post="bacterial infection.Cell Host Microbe7103â€&quot;114. 10.1016/j.chom.2010.01.01020159617 JaultP.LeclercT.JennesS.PirnayJ. P.QueY. A.ReschG.et al."/>
  <result pre="influenza virus-induced glucocorticoids compromise innate host defense against a secondary" exact="bacterial" post="infection.Cell Host Microbe7103â€&quot;114. 10.1016/j.chom.2010.01.01020159617 JaultP.LeclercT.JennesS.PirnayJ. P.QueY. A.ReschG.et al. (2019)."/>
  <result pre="recent trends.Eur. Rev. Med. Pharmacol. Sci.242006â€&quot;2011.32141569 KashJ. C.TaubenbergerJ. K. (2015)." exact="Infectious" post="disease theme issue the role of viral, host, and"/>
  <result pre="trends.Eur. Rev. Med. Pharmacol. Sci.242006â€&quot;2011.32141569 KashJ. C.TaubenbergerJ. K. (2015). Infectious" exact="disease" post="theme issue the role of viral, host, and secondary"/>
  <result pre="Infectious disease theme issue the role of viral, host, and" exact="secondary" post="bacterial factors in influenza pathogenesis.Am. J. Pathol.1851528â€&quot;1536. 10.1016/j.ajpath.2014.08.03025747532 KhalifaL.ShlezingerM.BeythS.Houri-HaddadY.Coppenhagen-GlazerS.BeythN.et"/>
  <result pre="disease theme issue the role of viral, host, and secondary" exact="bacterial" post="factors in influenza pathogenesis.Am. J. Pathol.1851528â€&quot;1536. 10.1016/j.ajpath.2014.08.03025747532 KhalifaL.ShlezingerM.BeythS.Houri-HaddadY.Coppenhagen-GlazerS.BeythN.et al."/>
  <result pre="10.1016/j.ajpath.2014.08.03025747532 KhalifaL.ShlezingerM.BeythS.Houri-HaddadY.Coppenhagen-GlazerS.BeythN.et al. (2016). Phage therapy against Enterococcus faecalis in" exact="dental" post="root canals.J. Oral Microbiol.8:32157. KimM.JoY.HwangY. J.HongH. W.HongS. S.ParkK.et al."/>
  <result pre="(2020). Antimicrobial activity of LysSS, a novel phage endolysin, against" exact="Acinetobacter" post="baumannii and Pseudomonas aeruginosa.J. Glob. Antimicrob. Res.10.1016/j.jgar.2020.01.005[Epub ahead of"/>
  <result pre="ahead of print]. 32006750 KimY. G.ParkJ. H.ReimerT.BakerD. P.KawaiT.KumarH.et al. (2011)." exact="Viral" post="infection augments Nod1/2 signaling to potentiate lethality associated with"/>
  <result pre="of print]. 32006750 KimY. G.ParkJ. H.ReimerT.BakerD. P.KawaiT.KumarH.et al. (2011). Viral" exact="infection" post="augments Nod1/2 signaling to potentiate lethality associated with secondary"/>
  <result pre="Viral infection augments Nod1/2 signaling to potentiate lethality associated with" exact="secondary" post="bacterial infections.Cell Host Microbe9496â€&quot;507. 10.1016/j.chom.2011.05.00621669398 KnezevicP.CurcinS.AleksicV.PetrusicM.VlaskiL. (2013). Phage-antibiotic synergism"/>
  <result pre="infection augments Nod1/2 signaling to potentiate lethality associated with secondary" exact="bacterial" post="infections.Cell Host Microbe9496â€&quot;507. 10.1016/j.chom.2011.05.00621669398 KnezevicP.CurcinS.AleksicV.PetrusicM.VlaskiL. (2013). Phage-antibiotic synergism :"/>
  <result pre="Elsevier). 10.1016/B978-0-12-809633-8.20986-2 KumarA.ChordiaN. (2017). â€œBacterial resistance against antibiotics,â€� in Drug" exact="Resistance" post="in Bacteria, Fungi, Malaria, and Cancer, edsAroraG.SajidA.KaliaV. (Cham: Springer),"/>
  <result pre="(2000). Pattern recognition receptors TLR4 and CD14 mediate response to" exact="respiratory" post="syncytial virus.Nat. Immunol.1398â€&quot;401. 10.1038/8083311062499 KutterE.De VosD.GvasaliaG.AlavidzeZ.GogokhiaL.KuhlS.et al. (2010). Phage"/>
  <result pre="a multidisciplinary future of phage therapy to combat multi-drug resistant" exact="bacterial" post="infections.Infect. Microbes Dis.21â€&quot;2. 10.1097/im9.0000000000000018 Lusiak-SzelachowskaM.Weber-DaÌ§browskaB.GÃ³rskiA. (2020). Bacteriophages and lysins"/>
  <result pre="Sin.35125â€&quot;133. 10.1007/s12250-019-00192-332125643 MacIntyreC. R.ChughtaiA. A.BarnesM.RiddaI.SealeH.TomsR.et al. (2018). The role of" exact="pneumonia" post="and secondary bacterial infection in fatal and serious outcomes"/>
  <result pre="MacIntyreC. R.ChughtaiA. A.BarnesM.RiddaI.SealeH.TomsR.et al. (2018). The role of pneumonia and" exact="secondary" post="bacterial infection in fatal and serious outcomes of pandemic"/>
  <result pre="R.ChughtaiA. A.BarnesM.RiddaI.SealeH.TomsR.et al. (2018). The role of pneumonia and secondary" exact="bacterial infection" post="in fatal and serious outcomes of pandemic influenza a"/>
  <result pre="A.BarnesM.RiddaI.SealeH.TomsR.et al. (2018). The role of pneumonia and secondary bacterial" exact="infection" post="in fatal and serious outcomes of pandemic influenza a"/>
  <result pre="(H1N1) pdm09.BMC Infect. Dis.18:637. 10.1186/s12879-018-3548-030526505 MaharP. D.WasiakJ.ClelandH.PaulE.GinD.WattersD. A.et al. (2014)." exact="Secondary" post="bacterial infection and empirical antibiotic use in toxic epidermal"/>
  <result pre="pdm09.BMC Infect. Dis.18:637. 10.1186/s12879-018-3548-030526505 MaharP. D.WasiakJ.ClelandH.PaulE.GinD.WattersD. A.et al. (2014). Secondary" exact="bacterial infection" post="and empirical antibiotic use in toxic epidermal necrolysis patients.J."/>
  <result pre="Infect. Dis.18:637. 10.1186/s12879-018-3548-030526505 MaharP. D.WasiakJ.ClelandH.PaulE.GinD.WattersD. A.et al. (2014). Secondary bacterial" exact="infection" post="and empirical antibiotic use in toxic epidermal necrolysis patients.J."/>
  <result pre="al. (2014). Secondary bacterial infection and empirical antibiotic use in" exact="toxic epidermal necrolysis" post="patients.J. Burn Care Res.35518â€&quot;524. 10.1097/bcr.000000000000006224988228 MalliaP.FootittJ.SoteroR.JepsonA.ContoliM.Trujillo-TorralboM. B.et al. (2012)."/>
  <result pre="patients.J. Burn Care Res.35518â€&quot;524. 10.1097/bcr.000000000000006224988228 MalliaP.FootittJ.SoteroR.JepsonA.ContoliM.Trujillo-TorralboM. B.et al. (2012). Rhinovirus" exact="infection" post="induces degradation of antimicrobial peptides and secondary bacterial infection"/>
  <result pre="al. (2012). Rhinovirus infection induces degradation of antimicrobial peptides and" exact="secondary" post="bacterial infection in chronic obstructive pulmonary disease.Am. J. Respir."/>
  <result pre="(2012). Rhinovirus infection induces degradation of antimicrobial peptides and secondary" exact="bacterial infection" post="in chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care"/>
  <result pre="Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial" exact="infection" post="in chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care"/>
  <result pre="induces degradation of antimicrobial peptides and secondary bacterial infection in" exact="chronic" post="obstructive pulmonary disease.Am. J. Respir. Crit. Care Med.1861117â€&quot;1124. 10.1164/rccm.201205-0806oc23024024"/>
  <result pre="of antimicrobial peptides and secondary bacterial infection in chronic obstructive" exact="pulmonary" post="disease.Am. J. Respir. Crit. Care Med.1861117â€&quot;1124. 10.1164/rccm.201205-0806oc23024024 ManoharP.TamhankarA. J.LeptihnS.RameshN."/>
  <result pre="and challenges ahead.Microorganisms7:84. 10.3390/microorganisms703008430889831 McCullersJ. A. (2011). Preventing and treating" exact="secondary" post="bacterial infections with antiviral agents.Antivir. Ther.16123â€&quot;135. 10.3851/imp173021447860 MiÈ©dzybrodzkiR.BorysowskiJ.Weber-DaÌ§browskaB.FortunaW.LetkiewiczS.SzufnarowskiK.et al."/>
  <result pre="challenges ahead.Microorganisms7:84. 10.3390/microorganisms703008430889831 McCullersJ. A. (2011). Preventing and treating secondary" exact="bacterial infections" post="with antiviral agents.Antivir. Ther.16123â€&quot;135. 10.3851/imp173021447860 MiÈ©dzybrodzkiR.BorysowskiJ.Weber-DaÌ§browskaB.FortunaW.LetkiewiczS.SzufnarowskiK.et al. (2012). Clinical"/>
  <result pre="ahead.Microorganisms7:84. 10.3390/microorganisms703008430889831 McCullersJ. A. (2011). Preventing and treating secondary bacterial" exact="infections" post="with antiviral agents.Antivir. Ther.16123â€&quot;135. 10.3851/imp173021447860 MiÈ©dzybrodzkiR.BorysowskiJ.Weber-DaÌ§browskaB.FortunaW.LetkiewiczS.SzufnarowskiK.et al. (2012). Clinical"/>
  <result pre="al. (2018). Innate immune cell suppression and the link with" exact="secondary" post="lung bacterial pneumonia.Front. Immunol.9:2943. 10.3389/fimmu.2018.0294330619303 MorrisD. E.ClearyD. W.ClarkeS. C."/>
  <result pre="Innate immune cell suppression and the link with secondary lung" exact="bacterial" post="pneumonia.Front. Immunol.9:2943. 10.3389/fimmu.2018.0294330619303 MorrisD. E.ClearyD. W.ClarkeS. C. (2017). Secondary"/>
  <result pre="lung bacterial pneumonia.Front. Immunol.9:2943. 10.3389/fimmu.2018.0294330619303 MorrisD. E.ClearyD. W.ClarkeS. C. (2017)." exact="Secondary" post="bacterial infections associated with influenza pandemics.Front. Microbiol.8:1041. 10.3389/fmicb.2017.0104128690590 MorrisD."/>
  <result pre="bacterial pneumonia.Front. Immunol.9:2943. 10.3389/fimmu.2018.0294330619303 MorrisD. E.ClearyD. W.ClarkeS. C. (2017). Secondary" exact="bacterial infections" post="associated with influenza pandemics.Front. Microbiol.8:1041. 10.3389/fmicb.2017.0104128690590 MorrisD. P. (2007)."/>
  <result pre="pneumonia.Front. Immunol.9:2943. 10.3389/fimmu.2018.0294330619303 MorrisD. E.ClearyD. W.ClarkeS. C. (2017). Secondary bacterial" exact="infections" post="associated with influenza pandemics.Front. Microbiol.8:1041. 10.3389/fmicb.2017.0104128690590 MorrisD. P. (2007)."/>
  <result pre="influenza pandemics.Front. Microbiol.8:1041. 10.3389/fmicb.2017.0104128690590 MorrisD. P. (2007). Bacterial biofilm in" exact="upper" post="respiratory tract infections.Curr. Infect. Dis. Rep.9186â€&quot;192. 10.1007/s11908-007-0030-317430699 NansenA.ThomsenA. R."/>
  <result pre="pandemics.Front. Microbiol.8:1041. 10.3389/fmicb.2017.0104128690590 MorrisD. P. (2007). Bacterial biofilm in upper" exact="respiratory" post="tract infections.Curr. Infect. Dis. Rep.9186â€&quot;192. 10.1007/s11908-007-0030-317430699 NansenA.ThomsenA. R. (2001)."/>
  <result pre="respiratory tract infections.Curr. Infect. Dis. Rep.9186â€&quot;192. 10.1007/s11908-007-0030-317430699 NansenA.ThomsenA. R. (2001)." exact="Viral" post="infection causes rapid sensitization to lipopolysaccharide: central role of"/>
  <result pre="tract infections.Curr. Infect. Dis. Rep.9186â€&quot;192. 10.1007/s11908-007-0030-317430699 NansenA.ThomsenA. R. (2001). Viral" exact="infection" post="causes rapid sensitization to lipopolysaccharide: central role of IFN-Î±Î².J."/>
  <result pre="Pseudomonas aeruginosa.Alexandria J. Med.5299â€&quot;105. 10.1016/j.ajme.2015.05.002 NyangachaR. M.OdongoD.OyiekeF.OchwotoM.KorirR.NgetichR. K.et al. (2017)." exact="Secondary" post="bacterial infections and antibiotic resistance among tungiasis patients in"/>
  <result pre="aeruginosa.Alexandria J. Med.5299â€&quot;105. 10.1016/j.ajme.2015.05.002 NyangachaR. M.OdongoD.OyiekeF.OchwotoM.KorirR.NgetichR. K.et al. (2017). Secondary" exact="bacterial infections" post="and antibiotic resistance among tungiasis patients in Western, Kenya.PLoS"/>
  <result pre="J. Med.5299â€&quot;105. 10.1016/j.ajme.2015.05.002 NyangachaR. M.OdongoD.OyiekeF.OchwotoM.KorirR.NgetichR. K.et al. (2017). Secondary bacterial" exact="infections" post="and antibiotic resistance among tungiasis patients in Western, Kenya.PLoS"/>
  <result pre="K.et al. (2017). Secondary bacterial infections and antibiotic resistance among" exact="tungiasis" post="patients in Western, Kenya.PLoS Negl. Trop. Dis.11e0005901. 10.1371/journal.pntd.000590128886013 PerryA."/>
  <result pre="Trop. Dis.11e0005901. 10.1371/journal.pntd.000590128886013 PerryA. K.GangC. H.ZhengD.HongT. A.ChengG. (2005). The host" exact="type I" post="interferon response to viral and bacterial infections.Cell Res.15407â€&quot;422. 10.1038/sj.cr.729030915987599"/>
  <result pre="H.ZhengD.HongT. A.ChengG. (2005). The host type I interferon response to" exact="viral" post="and bacterial infections.Cell Res.15407â€&quot;422. 10.1038/sj.cr.729030915987599 PiresD. P.MeloL. D.BoasD. V.SillankorvaS.AzeredoJ."/>
  <result pre="(2005). The host type I interferon response to viral and" exact="bacterial" post="infections.Cell Res.15407â€&quot;422. 10.1038/sj.cr.729030915987599 PiresD. P.MeloL. D.BoasD. V.SillankorvaS.AzeredoJ. (2017). Phage"/>
  <result pre="Phage therapy-advantages over antibiotics?Lancet356:141810.1016/s0140-6736(05)74059-9 PittetL. A.Hall-StoodleyL.RutkowskiM. R.HarmsenA. G. (2010). Influenza" exact="virus infection" post="decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae.Am."/>
  <result pre="therapy-advantages over antibiotics?Lancet356:141810.1016/s0140-6736(05)74059-9 PittetL. A.Hall-StoodleyL.RutkowskiM. R.HarmsenA. G. (2010). Influenza virus" exact="infection" post="decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae.Am."/>
  <result pre="online at: https://www.sciencemag.org/news/2020/04/antibiotic-treatment-covid-19-complications-could-fuel-resistant-bacteria(accessed June 15, 2020). RoquillyA.McWilliamH. E.JacquelineC.TianZ.CinottiR.RimbertM.et al. (2017)." exact="Local" post="modulation of antigen-presenting cell development after resolution of pneumonia"/>
  <result pre="(2017). Local modulation of antigen-presenting cell development after resolution of" exact="pneumonia" post="induces long-term susceptibility to secondary infections.Immunity47135â€&quot;147.28723546 SarkerS. A.SultanaS.ReutelerG.MoineD.DescombesP.ChartonF.et al."/>
  <result pre="of antigen-presenting cell development after resolution of pneumonia induces long-term" exact="susceptibility to" post="secondary infections.Immunity47135â€&quot;147.28723546 SarkerS. A.SultanaS.ReutelerG.MoineD.DescombesP.ChartonF.et al. (2016). Oral phage therapy"/>
  <result pre="cell development after resolution of pneumonia induces long-term susceptibility to" exact="secondary" post="infections.Immunity47135â€&quot;147.28723546 SarkerS. A.SultanaS.ReutelerG.MoineD.DescombesP.ChartonF.et al. (2016). Oral phage therapy of"/>
  <result pre="secondary infections.Immunity47135â€&quot;147.28723546 SarkerS. A.SultanaS.ReutelerG.MoineD.DescombesP.ChartonF.et al. (2016). Oral phage therapy of" exact="acute" post="bacterial diarrhea with two coliphage preparations: a randomized trial"/>
  <result pre="infections.Immunity47135â€&quot;147.28723546 SarkerS. A.SultanaS.ReutelerG.MoineD.DescombesP.ChartonF.et al. (2016). Oral phage therapy of acute" exact="bacterial" post="diarrhea with two coliphage preparations: a randomized trial in"/>
  <result pre="SarkerS. A.SultanaS.ReutelerG.MoineD.DescombesP.ChartonF.et al. (2016). Oral phage therapy of acute bacterial" exact="diarrhea" post="with two coliphage preparations: a randomized trial in children"/>
  <result pre="therapeutic cocktails to treat a patient with a disseminated resistant" exact="Acinetobacter" post="baumannii infection.Antimicrob. Agents Chemother.61: e00954â€&quot;17.28807909 SeguinP.LaviolleB.ChanavazC.DonnioP. Y.Gautier-LerestifA. L.CampionJ. P.et"/>
  <result pre="L.CampionJ. P.et al. (2006). Factors associated with multidrug-resistant bacteria in" exact="secondary" post="peritonitis: impact on antibiotic therapy.Clin. Microbiol. Infect.12980â€&quot;985. 10.1111/j.1469-0691.2006.01507.x16961634 SummersW."/>
  <result pre="Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâ€&quot;infected" exact="pneumonia" post="in Wuhan, China.JAMA3231061â€&quot;1069. WangH.AnthonyD.SelemidisS.VlahosR.BozinovskiS. (2018). Resolving viral-induced secondary bacterial"/>
  <result pre="novel coronavirusâ€&quot;infected pneumonia in Wuhan, China.JAMA3231061â€&quot;1069. WangH.AnthonyD.SelemidisS.VlahosR.BozinovskiS. (2018). Resolving viral-induced" exact="secondary" post="bacterial infection in COPD: A concise review.Front. Immunol.9:2345. 10.3389/fimmu.2018.0234530459754"/>
  <result pre="coronavirusâ€&quot;infected pneumonia in Wuhan, China.JAMA3231061â€&quot;1069. WangH.AnthonyD.SelemidisS.VlahosR.BozinovskiS. (2018). Resolving viral-induced secondary" exact="bacterial infection" post="in COPD: A concise review.Front. Immunol.9:2345. 10.3389/fimmu.2018.0234530459754 Weber-DabrowskaB.MulczykM.GÃ³rskiA. (2001)."/>
  <result pre="pneumonia in Wuhan, China.JAMA3231061â€&quot;1069. WangH.AnthonyD.SelemidisS.VlahosR.BozinovskiS. (2018). Resolving viral-induced secondary bacterial" exact="infection" post="in COPD: A concise review.Front. Immunol.9:2345. 10.3389/fimmu.2018.0234530459754 Weber-DabrowskaB.MulczykM.GÃ³rskiA. (2001)."/>
  <result pre="A concise review.Front. Immunol.9:2345. 10.3389/fimmu.2018.0234530459754 Weber-DabrowskaB.MulczykM.GÃ³rskiA. (2001). Bacteriophage therapy for" exact="infections" post="in cancer patients.Clin. Appl. Immunol. Rev.1131â€&quot;134. 10.1016/s1529-1049(01)00015-0 WilliamsA. E.EdwardsL.HumphreysI."/>
  <result pre="review.Front. Immunol.9:2345. 10.3389/fimmu.2018.0234530459754 Weber-DabrowskaB.MulczykM.GÃ³rskiA. (2001). Bacteriophage therapy for infections in" exact="cancer" post="patients.Clin. Appl. Immunol. Rev.1131â€&quot;134. 10.1016/s1529-1049(01)00015-0 WilliamsA. E.EdwardsL.HumphreysI. R.SnelgroveR.RaeA.RappuoliR.et al."/>
  <result pre="toxin of Escherichia coli (LTK63) provides generic protection against lung" exact="infectious" post="disease.J. Immunol.1737435â€&quot;7443. 10.4049/jimmunol.173.12.743515585869 YangX.YuY.XuJ.ShuH.LiuH.WuY.et al. (2020). Clinical course and"/>
  <result pre="Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study.Lancet Respir."/>
  <result pre="al. (2020). Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 </snippets>
</snippetsTree>
